Postmenopausal hormone therapy, SERMs, and coronary heart disease in women

[1]  H. S. Klopfenstein,et al.  Estrogen modulates responses of atherosclerotic coronary arteries. , 1990, Circulation.

[2]  R. Kauffman,et al.  Inhibition of vascular smooth muscle cell proliferation and arterial intimal thickening by a novel antiproliferative naphthopyran. , 1996, The Journal of pharmacology and experimental therapeutics.

[3]  M. Anthony,et al.  Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. , 1998, The Journal of clinical endocrinology and metabolism.

[4]  I. Laher,et al.  Estrogen and selective estrogen receptor modulator LY117018 enhance release of nitric oxide in rat aorta. , 1997, The Journal of pharmacology and experimental therapeutics.

[5]  P. Ridker.  Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease. , 1997, Haemostasis.

[6]  R. Epstein,et al.  Risk factors associated with women's compliance with estrogen replacement therapy. , 1997, Journal of women's health.

[7]  K. Ramanathan,et al.  Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. , 1997, American Journal of Cardiology.

[8]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[9]  S. Manuck,et al.  Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. , 1990, Arteriosclerosis.

[10]  E. Barrett-Connor,et al.  Hormone replacement therapy, heart disease, and other considerations. , 1998, Annual review of public health.

[11]  Susan R. Johnson,et al.  Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1996, JAMA.

[12]  J. Madans,et al.  Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. , 1997, American journal of epidemiology.

[13]  A. Folsom,et al.  Association of Hormone-Replacement Therapy with Various Cardiovascular Risk Factors in Postmenopausal Women , 1993 .

[14]  S. Reis,et al.  Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. , 1994, Circulation.

[15]  B. Wróblewska,et al.  Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery , 1993, British journal of pharmacology.

[16]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[17]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[18]  R. Cannon,et al.  Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. , 1996, Circulation.

[19]  M. Adams,et al.  Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[20]  P. M. Sarrel.  How Progestins Compromise the Cardioprotective Effects of Estrogens , 1995 .

[21]  J. Pirhonen,et al.  Long-term effects of hormone replacement therapy on the uterus and on uterine circulation. , 1993, American journal of obstetrics and gynecology.

[22]  K. McPherson,et al.  Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials , 1997, BMJ.

[23]  K. Fischer-Dzoga,et al.  The effect of estradiol on the proliferation of rabbit aortic medial tissue culture cells induced by hyperlipemic serum. , 1983, Experimental and molecular pathology.

[24]  A. LaCroix,et al.  Estrogen replacement therapy and prognosis after first myocardial infarction. , 1997, American journal of epidemiology.

[25]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[26]  C. Christiansen,et al.  EFFECTS OF RALOXIFENE ON BONE MINERAL DENSITY, SERUM CHOLESTEROL CONCENTRATIONS, AND UTERINE ENDOMETRIUM IN POSTMENOPAUSAL WOMEN , 1998 .

[27]  S. Reis,et al.  Long-term estrogen therapy abolishes acute estrogen-induced coronary flow augmentation in postmenopausal women. , 1997, American heart journal.

[28]  J. O’Keefe,et al.  Estrogen replacement therapy after coronary angioplasty in women. , 1997, Journal of the American College of Cardiology.

[29]  R. Cooney,et al.  Effects of tamoxifen on nitric oxide synthesis and neoplastic transformation in C3H 10T1/2 fibroblasts. , 1998, Cancer letters.

[30]  T. Bush,et al.  Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. , 1998, Circulation.

[31]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[32]  L. Kuller,et al.  Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. , 1998, JAMA.

[33]  Murota Seiitsu,et al.  Stimulation of prostaglandin cyclooxygenase and prostacyclin synthetase activities by estradiol in rat aortic smooth muscle cells , 1980 .

[34]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[35]  D. Mirvis,et al.  Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. , 1990, Archives of internal medicine.

[36]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[37]  R. Califf,et al.  Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. , 1996, Journal of the American College of Cardiology.

[38]  C. Viscoli,et al.  The relationship of treatment adherence to the risk of death after myocardial infarction in women. , 1993, JAMA.

[39]  K. Matthews,et al.  Prior to use of estrogen replacement therapy, are users healthier than nonusers? , 1996, American journal of epidemiology.

[40]  S. Rössner,et al.  Coronary Drug Project Research Group. , 1978, Atherosclerosis.

[41]  L. Baglietto,et al.  Tamoxifen reduces plasma homocysteine levels in healthy women. , 1998, British Journal of Cancer.

[42]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .

[43]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[44]  K. Kerlikowske,et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.

[45]  C. Viscoli,et al.  Differences between women and men in survival after myocardial infarction. Biology or methodology , 1990 .

[46]  P. Poole‐Wilson,et al.  Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease , 1993, The Lancet.

[47]  Susan R. Johnson,et al.  Symptom Relief and Side Effects of Postmenopausal Hormones: Results From the Postmenopausal Estrogen/Progestin Interventions Trial , 1998, Obstetrics and gynecology.

[48]  L. Mosca,et al.  Beneficial effect of hormone replacement therapy on lipoprotein (a) levels in postmenopausal women , 1999 .

[49]  J. Feyzi,et al.  Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. , 1994, Journal of the National Cancer Institute.

[50]  R. Karas,et al.  Human vascular smooth muscle cells contain functional estrogen receptor. , 1994, Circulation.

[51]  E. Barrett-Connor.  Postmenopausal estrogen and prevention bias. , 1991, Annals of internal medicine.

[52]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[53]  E. Gilbert-Barness.  The Death of Innocents: Observations on Sudden Infant Death Syndrome , 1998 .

[54]  P. Ganz,et al.  Estrogen Improves Endothelium-Dependent, Flow-Mediated Vasodilation in Postmenopausal Women , 1994, Annals of Internal Medicine.